Skip to main content

"This MAA submission, under an accelerated regulatory pathway, is an important step towards approval of our second product in the EEA and highlights Pharming’s ongoing commitment to advancing leniolisib as a treatment for patients with APDS."

- Anurag Relan | Chief Medical Officer
Cookies: This website uses cookies Check the cookies page for more information Accept Decline